Drug Information

Drug General Information
Drug ID
D05LTJ
Former ID
DCL001062
Drug Name
ISIS 325568
Drug Type
Antisense drug
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 1 [522094]
Therapeutic Class
Antisense
Company
Licensed to Ortho-McNeil, Inc.
Structure
Download
2D MOL

3D MOL
Formula
C20H19N5O3S2
Canonical SMILES
C1=CC=C2C(=C1)C(=CN2)CCNS(=O)(=O)C3=CC=CC(=C3)NC(=O)NC4<br />=NC=CS4
InChI
1S/C20H19N5O3S2/c26-19(25-20-21-10-11-29-20)24-15-4-3-5-16(12-15)30(27,28)23-9-8-14-13-22-18-7-2-1-6-17(14)18/h1-7,10-13,22-23H,8-9H2,(H2,21,24,25,26)
InChIKey
NYYVMDXWTXBRNW-UHFFFAOYSA-N
PubChem Compound ID
10455977
PubChem Substance ID
15477757, 22790277, 40583604, 74791898, 134339465
Target and Pathway
Target(s) mRNA of Glucagon receptor Target Info [551023]
Reactome Glucagon signaling in metabolic regulation
G alpha (q) signalling events
G alpha (s) signalling events
Glucagon-type ligand receptors
References
Ref 522094ClinicalTrials.gov (NCT00519727) Safety Study of ISIS 325568 in Healthy Volunteers. U.S. National Institutes of Health.
Ref 551023Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.